Objective: This study aimed to analyze the influence of antihypertensive, antihyperlipidemic, and mixed antidepressant medications on the failure and survival rates of dental implants. Methods: Out of a total of 2,815 patients who received 5,853 dental implants between 2012 and 2022, 655 patients with 2,004 implants met the inclusion criteria and were retrospectively reviewed. Patients were divided into four groups: control group (n = 512 patients with 1,581 implants), antihypertensive group (n₁ = 74 patients with 233 implants), antihyperlipidemic group (n₂ = 40 patients with 99 implants), and mixed antidepressant group (n₃ = 29 patients with 91 implants). Implant failure was defined according to the recommendations of the Pisa Consensus Conference of the International Congress of Oral Implantologists. Results: Kaplan-Meier analysis over a 10-year follow-up period showed significant differences in implant survival between the control group and all monotherapy groups. Implant survival was higher in patients receiving antihypertensive or antihyperlipidemic therapy and lower in those treated with mixed antidepressants. Log-rank tests confirmed statistically significant differences compared with controls (p < 0.05). Implant failure rates were 1.29% (n = 3/233) for the antihypertensive group, 1.01% (n = 1/99) for the antihyperlipidemic group, and 12.09% (n = 11/91) for the mixed antidepressant group, compared with 5.12% (n = 81/1581) in the control group. Mixed-effects survival analysis demonstrated a reduced risk of implant failure in patients receiving antihypertensive therapy (HR = 0.23) and antihyperlipidemic therapy (HR = 0.16), while mixed antidepressant medication was associated with a significantly increased risk of failure. Conclusion: Mixed antidepressant medications are associated with an increased risk of dental implant failure, while antihypertensive and antihyperlipidemic agents appear to have a protective effect, contributing to improved implant survival.
Background: Antihyperlipidemic medications are widely prescribed for the management of dyslipidemia and prevention of cardiovascular disease and may also influence bone metabolism, formation, and repair. However, their impact on peri-implant bone remodeling and dental implant survival remains insufficiently investigated. Objectives: The aim of this study was to evaluate the influence of antihyperlipidemic therapy on dental implant survival and failure rates over a ten-year period. Methods: A retrospective cohort study included 552 patients receiving 1680 dental implants between 2012 and 2022. Patients were divided into a control group (512 patients; 1581 implants) and a study group receiving antihyperlipidemic monotherapy (40 patients; 99 implants). Clinical, radiographic, and demographic data were collected and analyzed, and implant failure was assessed according to the established clinical criteria of the International Congress of Oral Implantologists. Results: Kaplan–Meier analysis demonstrated significantly better dental implant survival in patients receiving antihyperlipidemic therapy (log-rank p = 0.046). The failure rate was lower in the study group (1.01%) compared with the control group (5.12%). Cox regression analysis, adjusted for age, sex, implant diameter and length, insertion torque, and bone quality, showed that antihyperlipidemic therapy was associated with a markedly reduced risk of implant failure (HR = 0.16). Overall, the use of antihyperlipidemic medications was associated with a significantly lower risk of implant failure (p < 0.05), suggesting a beneficial effect on long-term dental implant survival. Conclusions: The present findings indicate that antihyperlipidemic therapy may be associated with improved dental implant survival and enhanced osseointegration. These results should be interpreted as hypothesis-generating and necessitate confirmation in future prospective randomized controlled studies with expanded and more balanced cohorts.